Spinal Cord Injury (SCI), as a devastating and life-altering neurological disorder, is one of the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and surgical decompression. Both the approaches have been observed to have adverse physiological effects on SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required for developing cell-based therapies. Multipotent stem cells, as a novel strategy for the treatment of tissue injury, may provide an effective therapeutic option against many neurological disorders. Mesenchymal stem cells (MSCs) or multipotent stromal cells can typically self-renew and generate various cell types. These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs), umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have remarkable potential for the development of regenerative therapies in animal models and humans with SCI. Herein, we summarize the therapeutic potential of human MSCs in the treatment of SCI.

脊髓损伤（SCI）是一种破坏性且改变生活的神经系统疾病，是最严重的健康问题之一。目前，急性SCI的治疗包括药物治疗和手术减压。已经观察到这两种方法对SCI患者都有不利的生理作用。因此，开发基于细胞的疗法迫切需要用于SCI管理的新的治疗靶标。多能干细胞作为一种治疗组织损伤的新策略，可以为许多神经系统疾病提供有效的治疗选择。间充质干细胞（MSC）或专能基质细胞通常可以自我更新并产生各种细胞类型。这些细胞通常是从骨髓（BM-MSC），脂肪组织（AD-MSC），脐带血（UCB-MSC）和胎盘（PMSC）中分离出来的。MSC在具有SCI的动物模型和人类中具有开发再生疗法的巨大潜力。本文中，我们总结了人类MSC在SCI治疗中的治疗潜力。